Combination Therapy for Use in Treating Retroviral Infections

Patent metadata

Field	Value
Publication number	US-2024285629-A1
Application number	US-202418648027-A
Country	US
Kind code	A1
Filing date	Apr 26, 2024
Priority date	Apr 18, 2017
Publication date	Aug 29, 2024
Grant date	—

Abstract

A pharmaceutical composition is provided comprising combination of antiretroviral drugs optionally in combination of pharmacokinetic boosters. The formulation is used for the treatment of diseases caused by retroviruses. The process of preparation of the formulation is also provided.

First claim

What is claimed is:

1 . A pharmaceutical composition comprising:
(i) a therapeutically effective amount of at least one non-nucleoside reverse transcriptase inhibitor comprising efavirenz, delavirdine, etravirine, rilpivirine or any combination thereof; and (ii) at least one pharmacokinetic booster or enhancer or derivative thereof comprising piperine, tetrahydropiperine, cis-piperine, trans-piperine, cis-trans piperine, trans,cis-piperine, cis,cis-piperine, trans, trans-piperine or a combination thereof.

2 . The pharmaceutical composition of claim 1 , further comprising at least one nucleoside reverse transcriptase inhibitor (NRTI) selected from the group consisting of: zidovudine; didanosine; stavudine; lamivudine; abacavir; adefovir; lobucavir; entecavir; apricitabine; emtricitabine; zalcitabine; dexelvucitabine; alovudine; amdoxovir; elvucitabine; AVX754; BCH-189; phosphazid; racivir; SP 1093V; stampidine; BCH-10652, p-L-FD4 (also called -L-D4C and named P-L-2′,3′-dicleoxy-5-fluoro-cytidene); DAPD, the purine nucleoside, (−)-P-D-2,6-diamino-purine dioxolane; and lodenosine (FddA), 9-(2,3-dideoxy-2-fluoro- -D-threo-pentofiiranosyl)adenine or any combination thereof.

3 . The pharmaceutical composition of claim 1 , further comprising at least one nucleotide reverse transcriptase inhibitor which comprises tenofovir, adefovir or any combination thereof.

4 . The pharmaceutical composition of claim 1 , wherein the composition comprises one or more pharmaceutically acceptable excipients selected from carriers, diluents, fillers, binders, lubricants, glidants, disintegrants, bulking agents, flavourants or any combination thereof.

5 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is for use in the treatment or prophylaxis of diseases caused by retroviruses.

6 . The pharmaceutical composition of claim 1 , wherein the at least one pharmacokinetic booster comprises piperine in the composition is present in an amount of from about 0.5 mg to about 400 mg.

7 . The pharmaceutical composition of claim 1 , wherein the ratio of the at least one reverse transcriptase inhibitor to the at least one pharmacokinetic booster or enhancer or derivative thereof is from about 100:1 to about 1:1 by weight.

8 . The pharmaceutical composition of claim 1 , wherein (i) the at least one pharmacokinetic booster or enhancer or derivative thereof reduces a dosing frequency of the at least one anti-retroviral drug that is administered to a patient; and (ii) the at least one pharmacokinetic booster or enhancer or derivative thereof increases the bioavailability of the at least one anti-retroviral drug from about 10% to about 70%.

9 . The pharmaceutical composition of claim 1 , wherein the composition is in the form of a tablet, mini-tablet, granules, sprinkles, capsules, sachets, powders, pellets, and the injectable composition is in the form of a solution, suspension, emulsion, lyophilized powder or in the form of a kit.

10 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for use in the treatment or prophylaxis of diseases caused by retroviruses.

11 . A method of treating diseases caused by retroviruses in a patient in need of such treatment, the method comprising: administering a pharmaceutical composition comprising:
(i) a therapeutically effective amount of at least one non-nucleoside reverse transcriptase inhibitor comprising efavirenz, delavirdine, etravirine, rilpivirine or any combination thereof, and (ii) at least one pharmacokinetic booster or enhancer or derivative thereof comprising piperine, tetrahydropiperine, cis-piperine, trans-piperine, cis-trans piperine, trans,cis-piperine, cis,cis-piperine, trans, trans-piperine or a combination thereof; and (iii) one or more pharmaceutically acceptable excipients comprising carriers, diluents, fillers, binders, lubricants, glidants, disintegrants, bulking agents, flavourants or any combination thereof.

12 . The method according to claim 11 , wherein the diseases caused by retroviruses comprises acquired immune deficiency syndrome or an HIV infection.

13 . A kit for treating disease caused by retroviruses, the kit comprising:
(i) a therapeutically effective amount of at least one non-nucleoside reverse transcriptase inhibitor comprising efavirenz, delavirdine, etravirine, rilpivirine or any combination thereof, and (ii) at least one pharmacokinetic booster or enhancer or derivative thereof comprising piperine, tetrahydropiperine, cis-piperine, trans-piperine, cis-trans piperine, trans,cis-piperine, cis,cis-piperine, trans, trans-piperine or a combination thereof, wherein the at least one non-nucleoside reverse transcriptase inhibitor, and the at least one pharmacokinetic booster or enhancer or derivative thereof are in a separate composition.

14 . The pharmaceutical composition of claim 1 , for use in enhancing the bioavailability of the oral anti-retroviral drug.

15 . The pharmaceutical composition of claim 14 , wherein:
(i) the at least one anti-retroviral drug is in a first composition and the at least one pharmacokinetic booster or enhancer or derivative thereof is in a second composition; or (ii) the at least one anti-retroviral drug and the at least one pharmacokinetic booster or enhancer or derivative thereof is combined in one composition.

16 . The pharmaceutical composition of claim 1 further comprising nevirapine or doravirine.

17 . The pharmaceutical composition of claim 16 further comprising doravirine, tenofovir alafenamide fumarate and emtricitabine with at least one pharmacokinetic enhancer or booster for once or twice a day administration.

18 . The pharmaceutical composition of claim 17 further comprising a pharmaceutically acceptable excipient such as microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

Assignees

• Cipla Ltd

Inventors

• Malhotra Geena
• Joshi Kalpana
• Raut Preeti

Classifications

• A61K31/675

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title

• A61K31/4525

  containing a five-membered ring with oxygen as a ring hetero atom · CPC title

• A61K31/4439

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61K9/28

  Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)} · CPC title

• A61P31/18

  for HIV · CPC title